Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 197

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 197
---
 operating activities of the Predecessor by raising capital. As of December 31, 2023, the
Predecessor has raised approximately $3,109. The Successor has declared it will continue financing Predecessor’s activity. If the Predecessor
will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may
be required to implement a cost reduction and/or delay part of its development programs.

| c. | Impact of the “Iron Swords” War on Israel: |

In October
2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and
military targets. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against
Hamas and other terrorist organizations in parallel to their continued rocket and terror attacks. In addition, Hezbollah have attacked
military and civilian targets in Northern Israel, to which Israel has responded, including through increased air and ground operations
in Lebanon. Since the war broke out, our subsidiary’s operations have not been adversely affected by this situation, and we have not experienced
disruptions to our development activities. However, the intensity and duration of Israel’s current war against Hamas and Hezbollah
is difficult to predict at this stage, as are such war’s economic implications on the Company’s business and operations and
on Israel’s economy in general.

On June 13,
2025, in light of continued nuclear threats and intelligence assessments indicating imminent attacks, Israel launched a pre-emptive strike
directly targeting military and nuclear infrastructure inside Iran aimed to disrupt Iran’s capacity to coordinate or launch further
hostilities against Israel, as well as disrupt its nuclear program. On June 25, 2025, a ceasefire between Israel and Iran took effect.
Nonetheless, hostilities between Israel and Iran may resume and further escalate, with both sides launching attacks against one another.
Company’s subsidiaries experienced disruptions to their work during such period. Since June 25, 2025, The Company’s subsidiaries have
been returning to full activity together with its local vendors and consultants. The Company doesn’t expect a material adverse effect
on its business.

The Company
continues to monitor its ongoing activities and will make adjustments in its business if needed, including updating any estimates or judgments
impacting its financial statements as appropriate.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Following the
closing of the Share Exchange agreement with Lipovation on July